Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.

被引：0
|
作者：
Cai, Mingyue [1 ]
Hong, Xiaoyang [1 ]
Huang, Wensou [1 ]
Guo, Yongjian [1 ]
Shi, Wenbo [1 ]
Liang, Licong [1 ]
Zhou, Jingwen [1 ]
Lin, Liteng [1 ]
Chen, Ye [1 ]
Zhu, Kangshun [1 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574
引用
收藏
页码：574 / 574
页数：1
相关论文
共 50 条
  • [31] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
  • [32] Phase II trial of sorafenib combined with on-demand transarterial chemoembolization for advanced stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage C): STAB study.
    Sato, Yozo
    Nishiofuku, Hideyuki
    Yasumoto, Taku
    Nakatsuka, Atsuhiro
    Matsuo, Kunihiro
    Kodama, Yoshihisa
    Abo, Daisuke
    Okubo, Hironao
    Takaki, Haruyuki
    Inaba, Yoshitaka
    Yamakado, Koichiro
    Hirota, Shozo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization
    Flohr, Felix
    Harder, Jan
    Seufert, Jochen
    Blum, Hubert E.
    Spangenberg, Hans C.
    HEPATOLOGY, 2008, 47 (06) : 2144 - 2144
  • [34] Phase I/II Study of Scheduled Interval Transarterial Chemoembolization Followed by Radiation Therapy for the Patients With Hepatocellular Carcinoma
    Yu, J. I.
    Park, H. C.
    Lim, D. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S454 - S454
  • [35] Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
    Kirstein, Martha M.
    Voigtlaender, Torsten
    Schweitzer, Nora
    Hinrichs, Jan B.
    Marquardt, Jens
    Woerns, Marcus-Alexander
    Kloeckner, Roman
    Fruendt, Thorben W.
    Ittrich, Harald
    Wacker, Frank
    Rodt, Thomas
    Manns, Michael P.
    Wege, Henning
    Weinmann, Arndt
    Vogel, Arndt
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (02) : 238 - 246
  • [36] Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
    Hu, Hao
    Duan, Zhenhua
    Long, Xiaoran
    Hertzanu, Yancu
    Shi, Haibin
    Liu, Sheng
    Yang, Zhengqiang
    PLOS ONE, 2014, 9 (05):
  • [37] Efficacy of apatinib in patients with sorafenib–transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study
    Yanyan Cao
    Tao Ouyang
    Fu Xiong
    Xuefeng Kan
    Lei Chen
    Bin Liang
    Chuansheng Zheng
    Hepatology International, 2021, 15 : 1268 - 1277
  • [38] A RANDOMIZED, CONTROLLED PHASE III TRIAL OF SORAFENIB WITH OR WITHOUT CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)
    Park, J. -W.
    Kim, Y. J.
    Kim, D. Y.
    Bae, S. H.
    Yeon, J. E.
    Han, S. Y.
    Hwang, J. S.
    Lee, Y. -J.
    Cheong, J. Y.
    Kwon, O. S.
    Kim, H. Y.
    Lee, H. C.
    Heo, J.
    Kim, B. H.
    Paik, S. W.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S857 - S857
  • [39] Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom
    Trojan, Joerg
    Cebon, Jonathan
    Liem, Andre K.
    Lipton, Lara
    Gupta, Charu
    Wu, Benjamin
    Bass, Michael
    Hollywood, Ellen
    Ma, Jennifer
    Bradley, Margaret
    Litten, Jason
    Saltz, Leonard B.
    ONCOLOGIST, 2017, 22 (07): : 780 - +
  • [40] Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Shao, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Ding, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345